Lewy Body Dementia Forecast in 12 Major Markets 2017-2027 Split by Gender and 5-Year Age Cohort

Dublin, March 27, 2017 -- Research and Markets has announced the addition of the "Lewy Body Dementia Forecast in 12 Major Markets 2017-2027" report to their offering.

This report provides the current prevalent population for Lewy Body Dementia across 12 Major Markets (USA, Canada, France, Germany, Russia, Italy, Spain, UK, Brazil, Japan, India and China) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Dementia with Lewy Bodies (DLB) is the second most frequent cause of age related neurodegenerative dementia, accounting for approximately a third of all dementias. The presence of Lewy bodies in the brain is linked to low levels of important chemical messengers and the loss of connection between nerve cells. This leads to the progressive death of nerve cells and loss of brain tissue.

Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Lewy Body Dementia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Lewy Body Dementia disease include:

• Problems with alertness and attention, which fluctuate over the course of a day
• Day-to-day memory problems
• Visual hallucinations
• Problems with motor control
• Somatoform disorders
• Issues organizing
• Rapid eye movement sleep disorders
• Problems with distance perception

Reasons to Buy

• Able to quantify patient populations in global Lewy Body Dementia market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Lewy Body Dementia and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Lewy Body Dementia prevalent population.
• Identify sub-populations within Lewy Body Dementia which require treatment.
• Gain an understanding of the specific markets that have the largest number of Lewy Body Dementia patients.

Key Topics Covered:

1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line prevalence for Lewy Body Dementia
10. Clinical features of Lewy Body Dementia patients
11. Symptoms of DLB patients
12. Abbreviations used in the report
13. Patient-Based Offering
14. Online Pricing Data and Platforms
15. References
16. Appendix

For more information about this report visit http://www.researchandmarkets.com/research/bhjxbw/lewy_body

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         [email protected]
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         U.S. Fax: 646-607-1907
         Fax (outside U.S.): +353-1-481-1716
         Related Topics: Central Nervous System Drugs